Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
- 1 July 1997
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 44 (3) , 269-274
- https://doi.org/10.1023/a:1005761302184
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.Journal of Clinical Oncology, 1993
- TAMOXIFEN USE, OESTROGEN BINDING AND SERUM LIPIDS IN POSTMENOPAUSAL WOMEN WITH BREAST CANCERAnz Journal of Surgery, 1990
- Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid CompositionJournal of Clinical Endocrinology & Metabolism, 1990
- A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancerBritish Journal of Cancer, 1989
- Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levelsBreast Cancer Research and Treatment, 1988
- Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast painJournal of Endocrinology, 1988
- Tamoxifen, serum lipoproteins and cardiovascular riskBritish Journal of Cancer, 1988
- Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifenAtherosclerosis, 1984
- Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breastMedical and Pediatric Oncology, 1979
- INCREASES IN STEROID BINDING GLOBULINS INDUCED BY TAMOXIFEN IN PATIENTS WITH CARCINOMA OF THE BREASTJournal of Endocrinology, 1978